منابع مشابه
Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly
THE CLINICAL DECISION TO CONTROL RISK FACTORS FOR CARDIOVASCULAR DISEASE (CVD) IN THE ELDERLY TAKES THE FOLLOWINGS INTO CONSIDERATION: (1) the elderly life expectancy; (2) the elderly biological age and functional capacity; (3) the role of cardiovascular disease in the elderly group; (4) the prevalence of risk factors in the elderly; and (5) The effectiveness of treatment of risk factors in the...
متن کامل“Silymarin”, a Promising Pharmacological Agent for Treatment of Diseases
Widespread use of herbal drugs because of their protective effects on different organs toxicity has been shown in many studies. These protective effects have been illustrated in the fields of nephrotoxicity, hepatotoxicity, viral hepatitis, cancer, in vitro fertilization, neurotoxicity, depression, lung diseases, prostate diseases etc. Silymarin has cytoprotection activities due to its antioxid...
متن کاملTreatment of dyslipidemia
Atherosclerotic cardiovascular disease (including coronary heart disease, stroke and peripheral arterial disease) is the leading cause of death globally. Abnormal blood lipids (dyslipidemia), smoking, and high blood pressure are responsible for more than 75% of cases. Aggressive low-density lipoprotein (LDL)-cholesterol lowering therapy, particularly statins, appear to be the most effective of ...
متن کاملNonpharmacologic treatment of dyslipidemia.
Cardiovascular disease is the number one cause of morbidity and mortality in the United States, with coronary heart disease (CHD) and myocardial infarction (MI) being the leading causes of death. The 5 major risk factors for CHD—hypertension, dyslipidemia, diabetes mellitus, smoking and obesity—account for 80% of the risk for CHD. Interventions, both pharmacologic and nonpharmacologic, can impr...
متن کاملTreatment approaches for diabetes and dyslipidemia.
BACKGROUND Dyslipidemia is an important risk factor for cardiovascular complications in persons with diabetes. Low-density lipoprotein-cholesterol (LDL-C) is the 'cornerstone' for assessment of lipoprotein-associated risk. However, LDL-C levels do not reflect the classic 'diabetic dyslipidemia' of hypertriglyceridemia and low high-density lipoprotein-cholesterol (HDL-C). Measurements of plasma ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Japanese Coronary Association
سال: 2018
ISSN: 1341-7703,2187-1949
DOI: 10.7793/jcoron.24.005